Institutional investors hold a significant stake in Abeona Therapeutics, influencing the stock's performance. Ownership structure reveals institutions own 39%, followed by hedge funds. Analysts and insider ownership also impact the company's trajectory. Despite public ownership, institutional decisions can sway the stock.